SOUTH SAN FRANCISCO, CA--(MARKET WIRE)--Jul 9, 2007 -- Theravance, Inc. (NasdaqGM:THRX - News) today announced results from its large Phase 2 clinical study evaluating the safety and efficacy of its investigational antibiotic, TD-1792, in the treatment of complicated skin and skin structure infections (cSSSI) caused by Gram-positive bacteria, including resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA). The study met its primary endpoint of non-inferiority compared to vancomycin, the standard of care for resistant Gram-positive infections, in the clinically evaluable population, and also met key secondary endpoints.
